BioDlink International Company Limited (01875.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 3.86

From 52W high−33.10%

Volume484000.00

Market capHKD 2.77B

P/E (TTM)—

P/S (TTM)4.7x

Div yield—

Key dataSep 18, 2026

Open

HKD 3.86

From 52W high

−33.10%

Volume

484000.00

Market cap

HKD 2.77B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−60.2x

P/E (TTM)

—

RSI (14)

52.3

MomentumView details →

1D Return

−0.39%

YTD Return

+52.80%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−60.2x

EV/Sales

4.9x

P/S (TTM)

4.7x

P/B (TTM)

3.9x

ProfitabilityView details →

Gross Margin

17.53%

Net Margin

−32.36%

EBITDA Margin

−8.15%

ROE (TTM)

−26.38%

ROA (TTM)

−13.82%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

−53.03%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+19.13%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−0.39%

YTD Return

+52.80%

1Y Return

+74.43%

RSI (14)

52.3

vs 50D SMA

+4.20%

vs 200D SMA

+1.62%

Capital & dividendView details →

Debt/Equity

0.57x

Current Ratio

2.15x

Quick Ratio

1.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.57B

Net Income (TTM)

−154.88M

Op. CF (TTM)

104.74M

Latest newsMore news →

TOT Biopharm reported an interim net loss of RMB 58.52 million for the six months ended June 30, 2026, compared with a net profit of RMB 4.06 million a year earlier, with revenue down 49.7% year-on-year to RMB 246 million.28d ago

Similar companies

Genor Biopharma Holdings Limited06998.HK Beijing Luzhu Biotechnology Co., Ltd.02480.HK Soleno Therapeutics, Inc.SLNO Precigen, Inc.PGEN Immunome, Inc.IMNM NewAmsterdam Pharma Company N.V.NAMS Find similar companies →

Latest newsMore news →

TOT Biopharm reported an interim net loss of RMB 58.52 million for the six months ended June 30, 2026, compared with a net profit of RMB 4.06 million a year earlier, with revenue down 49.7% year-on-year to RMB 246 million.28d ago